Vera Therapeutics Inc - Ordinary Shares - Class A
NASDAQ:VERA 4:00:00 PM EDT
Products, Regulatory
Vera Releases 36 Week Interim Analysis Of Phase 2b Clinical Trial Of Atacicept
Published: 01/30/2023 11:33 GMT
Vera Therapeutics Inc - Ordinary Shares - Class A (VERA) - Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of Iga Nephropathy; Patients in the 150 Mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria.
Vera Therapeutics Inc - Continuing Plans to Rapidly Advance Atacicept Into a Pivotal Phase 3 Trial in 1h 2023.
Vera Therapeutics-willprioritize Current Resources on Advancement of Atacicept in Iga Nephropathy Into Phase 3 Trial, Extending Cash Runway to Q4 2024.
Vera Therapeutics Inc - Safety Results Indicated That Atacicept Was Generally Well-tolerated.
Vera Therapeutics Inc - Continuing Plans to Rapidly Advance Atacicept Into a Pivotal Phase 3 Trial in 1h 2023.
Vera Therapeutics-willprioritize Current Resources on Advancement of Atacicept in Iga Nephropathy Into Phase 3 Trial, Extending Cash Runway to Q4 2024.
Vera Therapeutics Inc - Safety Results Indicated That Atacicept Was Generally Well-tolerated.